Wellstar International Inc. provides functional imaging systems through the use of infrared detection, specifically its wholly owned Trillenium Medical Imaging (TMI) System. This technology blends proprietary software with a highly durable and fully calibrated thermal detection device to record variances in body temperature. The TMI System provides a non-invasive procedure and is approved by the FDA as an Adjunctive Diagnostic screening procedure which can be used for early breast cancer detection, differential diagnosis of pain dysfunctions, (such as Reflex Sympathetic Dystrophy, Neuromuscular Skeletal Syndromes and Neurological disorders), the early detection of pressure ulcers and deep tissue injuries, as well as orthopedic applications.

Infrared thermal imaging is a non-invasive, imaging procedure involving the detection and recording of skin thermal patterns, providing visual and quantitative documentation. The interpretation of these temperatures and thermal patterns can play an important part in the development of a diagnosis. Because Infrared Imaging can display the variations in skin temperature patterns and these variations are known pathways of information, it can be invaluable as an integral part of the physical examination.

Trillennium Medical Imaging, has developed an innovative thermal imaging system designed for the evaluation and early detection of heat patterns within the body that indicate the presence of physical changes such as pressure ulcers, referred pain and metabolic changes within the breast. TMI’s infrared imaging system involves the detection and recording of skin temperature and injury patterns, providing visual and quantitative documentation to accurately capture body temperature data. TMI’s system map changes in skin blood flow by translating temperature data into pictures. The interpretation of these temperatures and thermal patterns can play an important role in the development of a diagnosis. The company’s system consists of proprietary imagers (“TMI 7800 Imager and TMI 7302 Imager”), operating software (“Image MHS 5.0 Software”) and a comprehensive data transmission and collection network, for which TMI has provisional patents.

The TMI technology and software is approved by the FDA as an Adjunctive Diagnostic screening procedure which can be used for early breast cancer detection, differential diagnosis of pain dysfunctions, (such as Reflex Sympathetic Dystrophy, Neuromuscular Skeletal Syndromes and Neurological disorders), the early detection of pressure ulcers and deep tissue injuries, as well as orthopedic applications. The Company’s imaging research concurrently looks to initiate consideration of thermography as a viable tool and a medical standard for predicting and preventing pressure ulcers in the medical community.